This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lamoth, F.
Right arrow Articles by Marchetti, O.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lamoth, F.
Right arrow Articles by Marchetti, O.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, February 2009, p. 785-787, Vol. 53, No. 2
0066-4804/09/$08.00+0     doi:10.1128/AAC.00891-08
Copyright © 2009, American Society for Microbiology. All Rights Reserved.

Reassessment of Recommended Imipenem Doses in Febrile Neutropenic Patients with Hematological Malignancies{triangledown}

F. Lamoth,1,{dagger} T. Buclin,2,{dagger} C. Csajka,2 A. Pascual,1 T. Calandra,1 and O. Marchetti1*

Infectious Diseases Service,1 Division of Clinical Pharmacology and Toxicology, Department of Medicine, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Lausanne, Switzerland2

Received 7 July 2008/ Returned for modification 4 September 2008/ Accepted 21 November 2008

Imipenem plasma concentrations were analyzed in 57 febrile neutropenic patients using the NONMEM program. The recommended 2-g/day regimen achieved coverage of the most common bacteria (MIC90 = 1 mg/liter) during the whole dosing interval in only 53% of patients. This goal was achieved in 90% of patients with 3 g/day.

* Corresponding author. Mailing address: Infectious Diseases Service, Department of Medicine, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Rue du Bugnon 46, CH-1011 Lausanne, Switzerland. Phone: 41 21 314 10 10. Fax: 41 21 314 10 18. E-mail: Oscar.Marchetti{at}chuv.ch

{triangledown} Published ahead of print on 1 December 2008.

{dagger} F. Lamoth and T. Buclin contributed equally to this work.

Antimicrobial Agents and Chemotherapy, February 2009, p. 785-787, Vol. 53, No. 2
0066-4804/09/$08.00+0     doi:10.1128/AAC.00891-08
Copyright © 2009, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Lamoth, F., Buclin, T., Pascual, A., Calandra, T., Marchetti, O. (2009). Imipenem underdosing as a cause of persistent neutropenic fever?. J Antimicrob Chemother 64: 665-667 [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»